The ageing process in men is marked by changes in body composition (loss of fat-free mass (FFM) and skeletal muscle, and gain in fat mass (FM)) and is associated with a decline in serum testosterone. Correlations between these aspects of ageing and the acknowledged role of exogenous testosterone in reversing the loss of FFM and gain in FM seen in adult men with congenital or acquired hypoandrogenism have led to the hypothesis that testosterone therapy in ageing men will result in favourable changes in body composition and may improve metabolic status and/or cardiovascular risk. Data from randomized controlled trials of testosterone therapy in ageing men addressing the endpoints of body composition and components of the metabolic syndrome and cardiovascular risk factors are reviewed, and the impact of the increasing prevalence of obesity on these relationships is considered.
Introduction
As men age beyond 40 years, they experience a decline in serum testosterone. The rate of fall in testosterone has been well documented in crosssectional 1,2 and longitudinal 3, 4 studies and is estimated to be 1-2% per annum, excluding the further impact of other variables such as ill health or concomitant medications, 1, 5 and possibly environmental factors. 6 The age-related fall in testosterone may impact the physical, sexual and/or psychological domains of a man's health; however, the relationship between ageing, declining sex steroids and symptomatology is complex. In particular, symptoms related to well being are often of a nonspecific nature. 7 As androgens are known to be important determinants of body composition, this provides an objective parameter by which to examine the impact of declining testosterone levels in ageing men.
Serum testosterone levels correlate positively with fat-free mass (FFM) and negatively with fat mass (FM), 8 and hypoandrogenism in young men is associated with a decline in FFM and skeletal muscle. 9 Testosterone replacement therapy increases FFM and decreases FM in men with acquired hypogonadism and hypoandrogenism due to ageing. 10, 11 Furthermore, muscle mass has been shown to correlate with strength (as measured by dynamometry) in healthy older men, 12 and in turn strength has been shown to positively correlate with bioavailable testosterone. 13 This has led to interest in the hypothesis that testosterone supplementation may attenuate or even reverse age-associated sarcopaenia and enhance the physical strength and well being of older males. Also, because of the integral nature of the relationship between body composition, and visceral fat in particular, and metabolic health, change in FM is an important outcome measure when considering the role of testosterone therapy in this cohort. In this context, there is growing recognition of the need to define the role played by testosterone in the metabolic status of men as they age.
Body composition and ageing
In western populations body mass index (BMI) increases with age throughout adult life until approximately 65 years, after which time it plateaus and then decreases. 14 The ageing process is associated with a decline in lean body mass and an increase in FM. 15 Total body potassium studies show that between 25 and 65 years of age, a man will lose 12 kg of lean body mass, at a rate of 0.4 kg per year beyond the fifth decade, with a similar increase in FM 15 and no appreciable change in overall weight. The loss of lean body mass represents a 20% decline between 25 and 65 years of age, 15 with skeletal muscle lost more rapidly than non-skeletal muscle mass. 16 This degree of change has been confirmed in other healthy cohorts. 8 Skeletal muscle mass is preserved until the fifth decade, and thereafter the age-associated loss is greater in men than in women. 17 The increase in FM represents a 60-85% increase over the same time period; the overall percentage of body fat increases from 19 to 35%. 8, 15, 18 The distribution of the FM also changes, with a more central accumulation in men after puberty, and therefore this gain in FM is predominantly reflected by increasing abdominal adiposity. Furthermore, it appears that it is the visceral adipose tissue component (measured by computerized tomography (CT) scan) that continues to increase as a function of age, 19 while the abdominal subcutaneous FM plateaus after the age of 30 years. 17, 18 The strongest anthropometric correlation with this intraabdominal fat is waist circumference. 20 The decrease in BMI after the age of 65 years reflects loss of both lean and FM, with further central redistribution of adipose tissue.
14 Others have described an accelerated loss of lean body mass after the age of 60 years, while FM continued to increase for another decade before it began to decline. 16 There is marked inter-individual variability in these changes 21 which in turn are influenced by alterations in total body weight. 22 The relationship of endogenous testosterone to body composition and the ability to intervene with the administration of exogenous testosterone is discussed below.
Testosterone and body composition
Skeletal muscle, fat-free mass and lean body mass The term lean body mass is often used synonymously with fat free mass. Lean body mass measurements were originally derived from total body potassium measurements based on the assumption that potassium was distributed only in non-fat tissues. The subsequent development of more precise methods of estimating FM directly, for example, dual X-ray absorptiometry (DEXA), has allowed the determination of FM and therefore FFM. In practice, lean body mass and FFM measurements give similar results. 23 Skeletal muscle mass can then be calculated from FFM measurements.
Studies in established androgen deficiency states. Congenital or acquired (as a result of disease states or induced experimentally) hypoandrogenism is associated with a decline in FFM and skeletal muscle. 9 Adult men with acquired hypogonadism, but otherwise in good health, have lower FFM than age-matched eugonadal controls, 10 and young men subjected to short-term hypoandrogenism induced by the administration of a gonadotrophin releasing hormone (GnRH) analogue demonstrate a decrease in FFM and a reduction in the rate of protein synthesis. 24 Older men undergoing androgen deprivation for treatment of prostate cancer also experience a decrease in lean body mass and muscle size. 25 Testosterone replacement in hypogonadal men increases lean muscle mass (as defined by CT) 10 and muscle size (quantified by magnetic resonance imaging (MRI)). 26 Muscle strength is also increased significantly with testosterone replacement. 26 In a further study of hypogonadal men (who had not received testosterone therapy for at least 2 years before enrollment in the trial), 6 months of testosterone treatment was associated with a 15% increase in FFM and a 20% increase in muscle mass. 27 The effects of testosterone administration on FFM in hypogonadal men have been summarized by Bhasin, 28 with increases of 1-5 kg being evident, dependent upon baseline serum testosterone and the dose and duration of the testosterone treatment regimen. The importance of testosterone dose on the magnitude of increase in skeletal muscle was clearly demonstrated in a study of healthy young men with experimentally induced hypogonadism in whom increases in FFM and muscle volume were directly proportional to the dose of testosterone administered and serum testosterone concentration. 29 In this study, the doses of intramuscular testosterone ranged from sub-physiological to clearly supra-physiological, and despite achieving serum total testosterone (TT) levels 480 nM, no plateau effect on increasing FFM was identified. Furthermore, supra-physiological doses of testosterone administered to eugonadal men have been shown to significantly increase FFM, muscle size and strength. 30 The effects of testosterone supplementation in the ageing male. The description of age-related sarcopaenia in the setting of the decline in serum testosterone in older men, and the knowledge that testosterone replacement increases FFM and muscle volume in young hypogonadal men, has led to the hypothesis that testosterone therapy in older men will increase FFM and skeletal muscle and may subsequently improve quality of life by increasing strength and stability. The largest placebo-controlled trial to test the hypothesis that testosterone supplementation in the older male Body composition, metabolic syndrome and testosterone in ageing men CA Allan et al will improve muscle mass and/or strength found that over 36 months of treatment, an increase in mean serum testosterone from 12.7 to 21.7 nM led to a 1.9 kg (3.5%) increase in lean mass; linear regression analysis showed an inverse relationship to pretreatment testosterone levels. 31 There was no demonstrable effect on dynamometric measures of muscle strength, although subjects with the lowest baseline testosterone levels reported that they perceived their physical performance to be improved. Other placebo-controlled trials have documented increases in lean body mass of 1.5-4.0 kg (Table 1 ). In the majority of these studies, baseline testosterone levels have been in the low normal young adult range and increased to within the upper part of the reference range. Duration of therapy may be important in predicting the magnitude of demonstrable effect, 32 and greater increases in lean body mass are seen in those studies employing supra-physiological androgen treatment regimens. [33] [34] [35] This is consistent with a recent study of graded doses of testosterone administered to healthy older men (rendered hypogonadal with a long-acting GnRH agonist) who, akin to the younger cohort previously studied, 29 demonstrated a dose-dependent increase in FFM, with no evidence of a plateau effect; 36 the observed magnitude of increase in FFM was comparable for the young and older men ( þ 7 to 8 kg or 12% increase from baseline). Of note, older men had a greater increase in serum testosterone than young men at set doses of testosterone, suggesting that older men have reduced testosterone clearance and may therefore potentially experience an enhanced tissue effect at a given testosterone dose. The increase in lean body mass has been linked to a decrease in muscle protein breakdown 35 and an increase in muscle protein synthesis. 37 Functional correlates of this increase in muscle mass are uncertain, 38 although measures of muscle strength assessed in short-term studies do suggest benefits with treatment. [39] [40] [41] Dihydrotestosterone 42 and human chorionic gonadotrophin (hCG) 43 over a 3-month period have also demonstrated improvement in selected aspects of muscle strength. While the favourable changes in FFM consistently demonstrated in short-term controlled studies may have important sequelae with regard to physical functioning, to date only surrogate predictors (strength, activity) of the desired end effects (for example, independent living, prevention of falls) have been studied.
Fat mass and regional adipose tissue distribution Studies in established androgen deficiency states. In parallel with the decrease in FFM seen in hypogonadal men, there is also an increase in FM. In a 
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Abbreviations: CT, computerized tomography; DEXA, dual X-ray absorptiometry; LBM; lean body mass; MRI, magnetic resonance imaging; ND, no data; NS, not significant; TBK, total body potassium. a Unless otherwise specified, treatment refers to testosterone. b Median.
P-value refers to within (active) group change. *P-value for comparison of change between active and placebo-treated groups.
Body composition, metabolic syndrome and testosterone in ageing men CA Allan et al study of men aged 22-69 years (mean age 53 years), hypogonadal subjects had 26% body fat compared to 19% in eugonadal men. 10 Similarly, induced hypogonadism (with a GnRH analogue) in young men resulted in a 1 kg increase in body fat over 10 weeks (body fat increased from 19 to 22%). 24 In older men with prostate cancer (and 22% body fat at baseline), the induction of profound hypogonadism resulted in a 9% increase in body fat after 48 weeks. 25 With respect to the role of testosterone replacement in otherwise healthy but hypoandrogenic men, the effects on FM were less marked than for the corresponding increase in lean body mass or FFM. Some studies have shown 10-15% decreases in FM with testosterone, 10, 27 with the decreases in FM correlated to the changes in serum testosterone. 44 Others however have failed to find a significant decline in FM 26 even with high-percentage body fat at baseline and an equivalent or longer treatment duration. 11, 41 Those studies failing to find a decrease in FM did not address the issue of regional fat distribution.
Quantitative CT analysis of hypogonadal men (mean age 52 years) has shown that they have a greater subcutaneous fat area and a trend towards an increased visceral fat area when compared to agematched eugonadal men. 45 Testosterone replacement, in addition to decreasing FM (as above), decreased subcutaneous fat by 12% and visceral fat by 6%. 10 Young men downregulated with GnRH and administered increasing doses of intramuscular testosterone 46 had a 20-40% increase in FM at sub-physiological testosterone replacement doses and a significant 10% decrease in FM at the highest (supra-physiological) testosterone dose. Abdominal subcutaneous fat volume (as quantified by MRI) increased at the lowest testosterone doses and the change in both subcutaneous and intra-abdominal (visceral) fat was negatively correlated with testosterone dose and serum testosterone concentration. Changes in fat distribution with both lowering and elevating serum testosterone were evenly distributed between the trunk and the appendices.
The effects of testosterone supplementation in the ageing male. Ageing is associated with increase in FM; the pattern of distribution of adipose tissue is also altered, with more marked increases in visceral as compared to subcutaneous FM. Furthermore, middle-aged men with visceral adiposity have lower serum total and free testosterone and sex hormone binding globulin (SHBG) levels than their peers without excess abdominal adipose tissue (as determined by CT). 47 Placebo-controlled trials of testosterone therapy in ageing men have shown decreases in FM ranging from 1 to 4.5 kg in studies of 3-36 months duration (Table 2 ). In studies of 36 months duration, 31 ,32 the magnitude of fat loss was greatest within the first 6 months of treatment, but unlike the increase in lean body mass, which plateaued after this time, the decrease in FM continued, albeit at a reduced rate. In these studies, a 70% 31 or greater 32 increase in mean serum testosterone from baseline readings of 12.7 nM 31 and 9.9 nM 32 led to 2.9 kg (12%) and 4.5 kg (16%) decreases in FM, respectively. A positive correlation between the change in FM and serum testosterone was seen in the Page et al. 32 study. Smaller decreases in FM are seen after 6-12 months of testosterone supplementation in older eugonadal men 35, 39, 48, 49 and following 90 days of treatment in overweight/obese hypogonadal older men. 50 Synthetic androgens (oxandrolone, oxymetholone) are associated with greater loss of FM than is native testosterone in short-term studies. 34, 51 In each of the studies in Table 2 , the mean baseline BMI of enrolled subjects was in the overweight range, thus making it likely that they included men with BMIs ranging from normal to obese. There are no studies, however, that have reported the observed change in FM as a function of baseline BMI. The magnitude of the decrease in FM identified in these studies may also be influenced by baseline serum testosterone, as noted in the 12-week study of oxandrolone therapy, 51 wherein men with baseline serum testosterone o10.4 nM had a significantly greater loss of FM than subjects with baseline serum testosterone 410.4 nM (À2.5 vs À1.5 kg; P ¼ 0.04).
Further to the reduction in total FM that has been consistently demonstrated, several studies have examined the effects of androgen supplementation on regional fat loss. Testosterone supplementation (oral for 8 months, transdermal for 9 months) of middle-aged men with mean BMI 29 kg/m 2 and abdominal obesity (and serum testosterone levels within the normal range) decreased visceral adiposity by 5-10% (0.4-0.6 kg), as assessed by CT, although total body fat (by total body potassium calculations) and subcutaneous adipose tissue mass (by CT) did not change. 52, 53 These findings were not able to be replicated with dihydrotestosterone (DHT), 54 and a further study of similar duration using intramuscular testosterone could not reproduce these results despite selecting for obese subjects. 55 Regional DEXA examinations in one study of older men showing significant loss of FM with testosterone treatment suggested that this loss was significant only in the appendices and not within the trunk. 31 More detailed analyses of regional adipose tissue distribution have yielded conflicting reports of the effects of androgens. Older eugonadal (baseline serum testosterone 15.3 nM) men with a mean BMI 26 kg/m 2 treated with intramuscular testosterone for 6 months had a non-significant 10% decrease in subcutaneous abdominal fat area, with no change in visceral or total intraabdominal fat (at the level of L4-L5 on MRI); 56 Body composition, metabolic syndrome and testosterone in ageing men CA Allan et al similarly, transdermal testosterone administered for 24 months to men with median BMI 28 kg/m 2 did not decrease visceral fat on CT examination. 57 Studies of 17-alkylated androgens (oxymetholone and oxandrolone) have shown both preferential loss of truncal FM 34 and an equivalent loss in both the trunk and the appendices. 51 Within the abdomen, both subcutaneous and visceral fat areas were decreased (as determined by a single MRI slice at the level of L4-L5), although neither change was significant when compared to change within the placebo group. 51 The change in subcutaneous fat area was greater in those men with lower baseline testosterone levels (o10.4 nM). Finally, dehydroepiandrosterone (DHEA) administered for 6 months to eugonadal, ageing overweight men resulted in a decrease in both visceral and subcutaneous abdominal fat, as analysed by crosssectional MRI scans; 58 treatment resulted in an 8% increase in serum testosterone levels.
A major deficiency in the literature is that there have been no studies of androgen replacement in older men that have examined the effects of treatment on visceral or subcutaneous fat area as a function of baseline adiposity and none has examined abdominal fat (visceral, subcutaneous) volumes.
One of the most important considerations when assessing the influence of testosterone on FM and visceral fat, in particular, is the potential to modify lipid metabolism and insulin sensitivity. These data are reviewed below.
Metabolic syndrome
Although there remains debate about the existence and definition of the term metabolic syndrome, 59, 60 it has found wide usage in describing that cluster of cardiovascular risk factors comprising abdominal adiposity, atherogenic dyslipidaemia, elevated blood pressure and elevated glucose (as an indicator of insulin resistance). The two most accepted criteria for the diagnosis are those of the United States Adult Treatment Panel III of the National Cholesterol Education Program (ATP III) 61 and the International Diabetes Federation (IDF). 62 A major difference between these criteria is the necessity of an elevated waist circumference (set according to ethnicity) by the IDF, underscoring the integral role played by visceral adiposity in the metabolic syndrome. The impact of testosterone therapy in Abbreviations: BMI, body mass index; CT, computerized tomography; DEXA, dual X-ray absorptiometry; MRI, magnetic resonance imaging; ND, no data; NS, not significant; TBK, total body potassium. a Unless otherwise specified, treatment refers to testosterone. b Decrease in visceral fat mass Po0.05 compared to baseline. c Median.
P-value refers to within (active) group change. *P-value for comparison of change between active and placebo treated groups.
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Relationship of endogenous testosterone to markers of cardiovascular risk in ageing men
When considering the association between serum testosterone and cardiovascular risk factors, it is important to be aware that the precise nature of the relationship between testosterone and individual cardiovascular risk factors may be obscured by failure to control for other related variables, for example, not controlling for BMI when investigating the relationships between testosterone and glycaemia and hyperlipidaemia. A study of middle-aged men classified by TT levels (10 vs 20 nM) found that systolic blood pressure, fasting glucose and total and low-density lipoprotein (LDL) cholesterol levels were inversely related to testosterone, but after adjusting for measures of adiposity and insulin resistance, only insulin levels and triglycerides remained significantly correlated with testosterone. 63 Negative correlations between testosterone and hypertension, 64 fasting plasma glucose, 65 hyperinsulinaemia 63 and visceral adiposity 66 are documented, and there is an uncertain association with high-density lipoprotein (HDL) cholesterol. 67, 68 Overall, the observational evidence suggests a neutral or beneficial effect of endogenous testosterone on cardiovascular risk factors in middle-aged and older men. 69 The effects of testosterone therapy on markers of cardiovascular risk in ageing men Hypertension. Testosterone therapy does not influence systolic or diastolic blood pressure readings in placebo-controlled trials. More detailed information about blood vessel function, specifically endothelial dysfunction, can be obtained by the technique of flow-mediated dilatation (FMD). 70 FMD measured in the brachial artery has a 95% positive predictive value for coronary artery endothelial dysfunction. 71 It declines with age in men, 72 although the relationship to serum testosterone is uncertain. 73 In eugonadal middle-aged men with coronary artery disease, supraphysiological doses of testosterone, administered intravenously, increased coronary blood flow. 74, 75 Three randomized controlled trials (RCTs) in older men with low-normal serum testosterone have examined the effect of physiological androgen replacement on vascular reactivity. 42, 76, 77 No change in FMD was seen with 3 months of DHT 42 or hCG 76 or with 12 months of transdermal testosterone. 77 FMD was increased with short-term physiological and acute supraphysiological testosterone treatments in middleaged men with underlying coronary artery disease. 78 In contradiction to the above data suggesting that testosterone has either a neutral or beneficial effect on vascular reactivity, men undergoing androgen deprivation for prostate cancer show increased FMD 79 and hypogonadal men exhibit increased FMD compared to their eugonadal peers; this is reversed by testosterone replacement. 80, 81 More work is needed to clarify the relationship between testosterone and vascular reactivity.
Lipids. Many of the studies in ageing men have shown limited effects of testosterone treatment on lipid profiles, with falls of approximately 10% in total and LDL cholesterol, 82, 83 although accompanied by falls of approximately 10% in HDL cholesterol. A meta-analysis of intramuscular testosterone treatment of hypogonadal men of all ages (mean TT 1.7 nM at baseline) suggested a dosedependent fall not only in total and LDL cholesterol but also in HDL cholesterol; 84 the decline in HDL cholesterol became less prominent with age and with prolonged treatment. 85 Placebo-controlled studies in which serum testosterone was increased within the healthy young adult male normal range showed minimal effects on total and LDL cholesterol and triglycerides, although the decline in HDL cholesterol levels was significant in two of four studies of 12 months or longer 86 (Table 3) . Oxandrolone was associated with unfavourable lipid changes. 51 There are insufficient data from randomized controlled trials to conclude whether the route of administration of testosterone is a significant determinant of the observed changes in lipid profiles. 83 Insulin resistance. An inverse association has been reported between endogenous testosterone levels and either hyperinsulinaemia 63 or an increased likelihood of developing type II diabetes mellitus. 87 Furthermore, clinical trial data documenting a decrease in FM, in particular a reduction in visceral adipose tissue, with testosterone therapy have led to the hypothesis that testosterone therapy may improve insulin sensitivity. 88. Results from studies of testosterone therapy addressing this matter have recently been reviewed. 89 Young, lean subjects did not demonstrate any change in insulin sensitivity across a wide range of serum testosterone levels in a dose-response study, despite a dose-related reduction in FM. 90 Centrally obese middle-aged men receiving testosterone showed an improvement in insulin sensitivity (by hyperinsulinaemic/euglycaemic clamp studies) and a lowering of serum insulin levels; 52 however, these results were not seen with DHT 53 or oxandrolone (when administered to a similarly obese cohort). 55 In ageing men, hCG administered for 3 months did not affect insulin sensitivity (as measured by euglycaemic clamp). 76 It is unclear as to whether changes in serum testosterone mediate insulin sensitivity independent of their effect on FM (specifically visceral fat). Comparison of data sets is difficult as those middle-aged men showing improved insulin sensitivity had higher FM and greater waist circumference at baseline 52 Body composition, metabolic syndrome and testosterone in ageing men CA Allan et al than the ageing men treated with hCG. 76 Furthermore, the middle-aged cohort had significant visceral fat loss with treatment, 52 and although total FM declined in the older men, there are no data regarding regional adipose tissue changes; 76 it is also possible that the duration of hCG treatment was insufficient. Although anabolic steroids (oxandrolone) demonstrate a significant reduction in abdominal fat, they have been associated with insulin resistance, thought to be mediated through hepatotoxicity.
Conclusion: the role of testosterone therapy in ageing men?
Evidence from randomized controlled trials of testosterone therapy in ageing men suggests that with respect to body composition and specifically FM, those men most likely to benefit from therapy are those with low baseline testosterone levels 32, 50 who receive therapy for in excess of 12 months. 31, 32 While there are little data examining the effect of therapy as a function of baseline FM, it is plausible to hypothesize that those men with the greatest amount of body fat may receive the greatest benefit from testosterone therapy in this regard. Indeed it may be that ageing males with a high proportion of body fat and those with age-related hypoandrogenism represent overlapping cohorts. In the Massachusetts Male Aging Study, obese men (with no other comorbidities) had TT levels 25% lower than their non-obese peers 1 and increasing BMI was as important as age in influencing the decline in serum testosterone experienced by older men. 5 In a cohort of ageing Australian men with symptoms suggestive of hypoandrogenism, 12.1% of obese men but only 0.8% of non-obese men had TT level o8 nM. 91 As the worldwide prevalence of obesity increases, in the United States, 36% of men aged 60-74 years are obese 92 (an increase of 12% between 1988 to 1994 and 1999 to 2000), it is likely that the number of men considered to have age-related hypoandrogenism will increase in parallel. Given the strong association of obesity with metabolic syndrome 61 and excess cardiovascular morbidity and mortality, 93, 94 the question as to whether testosterone therapy in older men with low testosterone levels (and likely accompanying obesity) will modify metabolic and cardiovascular risk is a timely and pertinent one.
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